Amylyx Pharmaceuticals, Inc. AMLX
29.20 USD +1.16 (+4.14%)
At closeNov 3, 2026, 4:01 PM EST
29.20 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
28.21 Day range 29.46
10.83 52-week range 41.14
- YTD
- +141.72%
- 1 year
- +114.71%
Financial health
Altman Z-Score
81.35 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -7.9×
FY 2019 5y median -7.9× FY 2025
P/S 0.0×
FY 2019 5y median 2.6× FY 2025
P/B 3.7×
FY 2019 5y median 2.3× FY 2025
P/FCF -9.3×
FY 2019 5y median -9.3× FY 2025
EV/EBITDA -6.4×
FY 2019 5y median -6.4× FY 2025
EV/Sales 0.0×
FY 2019 5y median 2.1× FY 2025
FCF Yield -10.8%
FY 2019 5y median -7.4% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 51.8% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -47.4%
FY 2019 5y median -47.4% FY 2025
ROIC -49.3%
FY 2019 5y median -58.0% FY 2025
ROA -43.5%
FY 2019 5y median -50.7% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2019 FY 2025
Operating Income 51.3%
FY 2019 FY 2025
EPS (diluted) 65.5%
FY 2019 FY 2025
Free Cash Flow 26.4%
FY 2019 FY 2025
Financial Health
Current Ratio 14.3×
FY 2019 5y median 6.7× FY 2025
Quick Ratio 14.3×
FY 2019 5y median 6.7× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 1.5×
FY 2019 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31